Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study
- 12 July 2014
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (8) , 2374-2382
Abstract
OBJECTIVE To study the ability of lipid variables to predict incident coronary artery disease (CAD) events in patients with type 1 diabetes at different stages of nephropathy. RESEARCH DESIGN AND METHODS Patients (n = 3,520) with type 1 diabetes and available lipid profiles participating in the Finnish Diabetic Nephropathy Study (FinnDiane) were included in the study. During a follow-up period of 10.2 years (8.6-12.0), 310 patients suffered an incident CAD event. RESULTS Apolipoprotein B (ApoB)/ApoA-I ratio was the strongest predictor of CAD in normoalbuminuric patients (hazard ratio 1.43 [95% CI 1.17-1.76] per one SD increase), and ApoB was the strongest in macroalbuminuric patients (1.47 [1.19-1.81]). Similar results were seen when patients were stratified by sex or glycemic control. LDL cholesterol was a poor predictor of CAD in women, normoalbuminuric patients, and patients with HbA(1c) below the median (8.3%, 67 mmol/L). The current recommended triglyceride cutoff of 1.7 mmol/L failed to predict CAD in normoalbuminuric patients, whereas the cohort median 0.94 mmol/L predicted incident CAD events. CONCLUSIONS In patients with type 1 diabetes, the predictive ability of the lipid variables differed substantially depending on the patient's sex, renal status, and glycemic control. In normoalbuminuric patients, the ratios of atherogenic and antiatherogenic lipoproteins and lipids were the strongest predictors of an incident CAD event, whereas in macroalbuminuric patients, no added benefit was gained from the ratios. Current treatment recommendations may need to be revised to capture residual CAD risk in patients with type 1 diabetes.Keywords
This publication has 41 references indexed in Scilit:
- Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?Diabetologia, 2013
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular diseaseEMBO Molecular Medicine, 2012
- Nonenzymatic glycation of high‐density lipoprotein impairs its anti‐inflammatory effects in innate immunityDiabetes/Metabolism Research and Reviews, 2011
- In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications StudyDiabetologia, 2010
- The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 DiabetesDiabetes, 2009
- Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoproteinBiochemical Society Transactions, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trialThe American Journal of Cardiology, 1995